Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.18%
#3 CoW Protocol CoW Protocol +44.40%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +26.78%
#6 Walrus Walrus +24.24%
#7 Codatta Codatta +19.91%
#8 Enso Enso +18.69%
#9 Collector Crypt Collector Crypt +14.14%
#10 The Black Bull The Black Bull +13.35%
Coin of the day
EXOD EXOD
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Rangering i aksjer #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Aksjekurs
$0.117
Sist synkronisert: 2025-04-04
Markedsverdi
$2.45M
Endring (1 dag)
-13.59%
Endring (1 år)
0.00%
Land
US
Handel Carmell Therapeutics Corporation (CTCX)

Kategori

Healthcare
Inntekter for Carmell Therapeutics Corporation (CTCX)
Inntekter i Jun 2026 TTM: $-6.79M
Ifølge Carmell Therapeutics Corporation sine nyeste økonomiske rapporter er selskapets nåværende resultat $-6.79M. I 2023 hadde selskapet et resultat på $-16.21M, en nedgang sammenlignet med resultatet i 2022, som var $-9.05M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Carmell Therapeutics Corporation fra 2021 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-6.79M -36.81%
2024 $-10.75M -33.68%
2023 $-16.21M 79.04%
2022 $-9.05M 2,647.97%
2021 $-329.38K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -77,766.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -28,821.01%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -44,355.62%
BE